IngredientsLeucyl-L-isoleucine, systematically abbreviated as L-Leu-L-Ile or Leu-Ile, is a naturally occurring dipeptide formed by the covalent joining of the two branched-chain amino acids (BCAAs) L-leucine (N-terminal residue) and L-isoleucine (C-terminal residue) via a standard peptide bond. Leucyl-Isoleucine is a dipeptide composed of leucine and isoleucine. It is an incomplete breakdown product of protein digestion or protein catabolism.
The compound is registered in the PubChem database under CID 435718. Its molecular formula is C12H24N2O3. Both constituent amino acids are members of the branched-chain amino acid (BCAA) family; L-isoleucine is an essential amino acid and one of the three branched-chain amino acids (BCAAs) present in all proteins, as is L-leucine. The dipeptide is distinct from its sequence isomer L-isoleucyl-L-leucine (Ile-Leu, CID 73949006), in which the residue positions are reversed — a distinction that, as discussed in the scientific evidence section below, carries measurable biological significance.
Because both leucine and isoleucine carry exclusively aliphatic, non-polar side chains, L-Leu-L-Ile is classified as a fully hydrophobic dipeptide. Dipeptides with at least one hydrophobic residue — lacking a functional group — such as Val, Leu, Ile and Phe have a high propensity to form crystal structures that are divided into hydrophobic and hydrophilic layers.
The solid-state behaviour of L-Leu-L-Ile has been studied in crystallographic detail by Görbitz at the University of Oslo. L-Leu-L-Ile (LI) has been obtained as two distinct hydrates: a 0.75 hydrate (CSD refcode ETIWIN) that is isostructural to the Leu-Val analogue, and a 2.5 hydrate with extensive water channels (CSD refcode HIZCOJ). Unlike several other dipeptides with two hydrophobic residues, l-Leu-l-Ile had not previously been obtained as an alcohol solvate, forming instead these two different hydrates; formation of a co-crystal was achieved by using a 2,2,2-trifluoroethanol solution. The resulting structure is divided into hydrophilic and hydrophobic layers.
The hydrogen-bonding architecture characteristic of such layered structures has been described in detail: the hydrophilic layers include head-to-tail chains with two of the three N-terminal amino H atoms acting as donors and the C-terminal carboxylate group as acceptor, and a chain using the peptide N–H group as donor; the third amino H atom finds an acceptor in a polar side chain or, when both residues are hydrophobic, in a co-crystallized solvent molecule.
L-Leu-L-Ile is not an isolated plant or animal organ used in the traditional botanical sense; rather, it is a dipeptide that arises endogenously as a product of the proteolytic digestion of dietary proteins. Any protein-containing food that contains both L-leucine and L-isoleucine residues in adjacent sequence positions can, upon enzymatic hydrolysis in the gastrointestinal tract or during food processing, yield this dipeptide.
Whey protein has been established as a particularly rich source from which this and related BCAA dipeptides can be generated. In earlier studies it was shown that dietary whey protein increased skeletal muscle and liver glycogen content in exercise-trained rats; however, little was known about whether individual ingredients of whey protein stimulate skeletal muscle glycogen accumulation, and the aim of subsequent research was to identify bioactive peptides in whey protein hydrolysates (WPH) which stimulated glucose uptake and glycogen synthesis rate in skeletal muscles. Branched-chain amino acid (BCAA)-containing dipeptides in WPH were identified using LC/MS/MS; in earlier studies dietary whey protein had been shown to increase skeletal muscle and liver glycogen content in exercise-trained rats. The BCAA-containing dipeptides Ile-Val, Leu-Val, Val-Leu, Ile-Ile, Leu-Ile, Ile-Leu, and Leu-Leu were detected in the WPH by LC/MS/MS.
Post-ingestion plasma detection confirms that these dipeptides cross the intestinal barrier intact and enter systemic circulation. Plasma dipeptide levels from WPH ingestion were extremely low compared with leucine levels; for example, the plasma levels of Leu-Ile were measured at 1.7 (SE 0.2) nmol/l in the WPH group. These dipeptides were not detected in the free amino acid group, confirming that their appearance in plasma is specifically attributable to the hydrolysate form of dietary protein rather than free amino acid supplementation.
More broadly, BCAA-containing dipeptides including Leu-Ile arise naturally from the enzymatic hydrolysis of a wide range of animal-derived proteins. The dipeptide can be prepared by any production method, including an extraction/purification method of a naturally derived substance obtained by hydrolysis of a natural product or protein, a chemical synthesis method in which a peptide bond is formed between amino acids by a solid or liquid phase method, or a biochemical synthesis method in which amino acids are bonded using an enzyme or microorganism.
Leucyl-L-isoleucine as a discrete, identified chemical entity has no documented history of traditional or folk medicinal use by any specific culture or time period. This compound was not isolatable or identifiable by traditional practitioners; its existence as a distinct bioactive molecule became recognizable only with the advent of modern peptide chemistry, LC/MS/MS analytical techniques, and protein hydrolysate research in the late twentieth and early twenty-first centuries.
The historical context for its discovery lies in the long-established traditional use of fermented, hydrolyzed, or partially digested protein foods — such as fermented dairy products, fermented soy foods, and bone broths — across many cultures. These preparations generate protein hydrolysates rich in di- and tripeptides of the type now known to include Leu-Ile as a component. However, attribution of any specific health effect of such traditional foods specifically to Leu-Ile as an isolated compound would be speculative and is not supported by the available scientific literature. The compound's scientific investigation began with the systematic study of bioactive peptides derived from whey protein hydrolysates, primarily in the 2000s and 2010s.
Leucyl-L-isoleucine is itself the sole active entity under consideration; it is not an extract containing multiple constituents. Its biological activity derives directly from its dipeptide structure, specifically:
The primary mechanism established in preclinical research is stimulation of glucose uptake in skeletal muscle through translocation of glucose transporter type 4 (GLUT-4) to the plasma membrane via signaling pathways that operate independently of the classical insulin receptor cascade. Stimulation of glucose uptake by Ile-Leu was completely inhibited by treatment with either LY294002 (a PI3-kinase inhibitor) or GF109203X (an atypical protein kinase C inhibitor) in both L6 cells and isolated muscles, indicating that the pathway requires both phosphoinositide 3-kinase (PI3K) and atypical protein kinase C (aPKC). These results suggest that BCAA-containing bioactive dipeptides in WPH stimulate glucose uptake in skeletal muscles via the PI3-kinase and aPKC pathways, resulting in increased skeletal muscle glycogen contents.
This is mechanistically relevant because the insulin signalling pathway operates through PI3K followed by Akt (PKB), which in turn phosphorylates AS160 to trigger GLUT-4 vesicle translocation. The peptide promotes glucose uptake into cells such as muscle cells and liver cells, particularly muscle cells; in muscle cells, insulin binds to an insulin receptor to cause activation of phosphoinositide 3-kinase (PI3K) downstream of an insulin receptor signal, then via several signal transductions, translocates glucose transporter-4 (GLUT-4) to the surface of a cell. The involvement of aPKC rather than conventional PKB/Akt suggests a partially overlapping but distinct route of GLUT-4 mobilization.
Supporting the insulin-independent character of this effect: L-isoleucine (a constituent amino acid of Leu-Ile) has been investigated separately; single oral administration to SD rats significantly reduced plasma glucose level at 30 and 60 min in an oral glucose tolerance test, while plasma insulin levels were also lower than those of the control group, revealing that insulin secretion was not affected. Signaling pathway analysis in C2C12 myotubes suggested that similar to leucine, PI3K and PKC were involved in the enhancement of glucose uptake by isoleucine.
Beyond acute glucose uptake, the dipeptide appears to promote downstream glycogen synthesis. Ile-Leu increased glycogen contents in isolated muscles. Isolated muscles were incubated with or without 1 mM dipeptides along with inhibitors, followed by measurement of 2-deoxyglucose uptake; isolated muscles were incubated for 3 hours with or without 1 mM Ile-Leu to determine glycogen synthesis rate. The Leu-Ile sequence isomer has also been shown to be active in the context of GLUT-4 translocation in rodent skeletal muscle in vivo (see Section 6 below).
Leucine is a well-established activator of the mechanistic target of rapamycin (mTOR) pathway. Among various amino acids, leucine is known to promote protein synthesis in skeletal muscle by activating the mTOR signaling factor. Research on whey protein hydrolysates — which contain Leu-Ile and related dipeptides — has raised the hypothesis that BCAA-containing dipeptides may contribute to mTOR-mediated signalling at concentrations lower than those required by free leucine alone: certain bioactive peptides in WPH may also activate S6K1 via phosphorylation without activating mTOR; plasma levels of dipeptides were elevated markedly after ingestion of WPH. Additional studies are required to determine whether these dipeptides caused stimulation of mTOR signalling at lower plasma concentrations than leucine. This remains an open hypothesis; no study has yet isolated Leu-Ile specifically and measured its independent effect on mTOR signalling in vivo.
Evidence level: Preclinical (in vitro and animal); no published human clinical trials specific to isolated Leu-Ile.
The foundational study was conducted by Morifuji, Koga, Kawanaka, and Higuchi (2009) at Meiji Seika Kaisha Ltd., published in the Journal of Nutritional Science and Vitaminology. The aim of this study was to identify bioactive peptides in whey protein hydrolysates (WPH) which stimulated glucose uptake and glycogen synthesis rate in skeletal muscles; BCAA-containing dipeptides in WPH were identified using LC/MS/MS; L6 myotubes and isolated epitrochlearis muscles were used for the glucose uptake assays. The BCAA-containing dipeptides Ile-Val, Leu-Val, Val-Leu, Ile-Ile, Leu-Ile, Ile-Leu, and Leu-Leu were detected in the WPH by LC/MS/MS; these dipeptides caused significant stimulation in glucose uptake rate in the L6 myotubes.
The concentration used in the cell and tissue incubation experiments was specified: the myotubes and muscles were incubated with or without 1 mM dipeptides, LY294002 (a phosphoinositide 3-kinase inhibitor), or GF102903X (an atypical protein kinase C inhibitor), followed by measurement of 2-deoxyglucose uptake. Employing rat L6 myotubes and isolated epitrochlearis muscles, Morifuji et al. showed that branched chain amino acid-containing bioactive dipeptides in whey protein hydrolysate (Ile-Val, Leu-Val, Val-Leu, Ile-Ile, Leu-Ile, Ile-Leu) significantly stimulate glucose uptake in the L6 myotubes, while Ile-Leu, the main component in whey protein hydrolysate, stimulates glucose uptake also in isolated muscles.
A subsequent animal study specifically addressed the Leu-Ile sequence isomer in vivo. This study (Morato, Lollo, Moura et al., published in Food Chemistry, 2013) used Wistar rats divided into seven groups. Forty-nine animals were divided into 7 groups (n = 7) and received by oral gavage 30% glucose plus 0.55 g/kg body mass of the following WPH components: (a) control; (b) WPH; (c) L-isoleucine; (d) L-leucine; (e) L-leucine plus L-isoleucine; (f) L-isoleucyl-L-leucine dipeptide; (g) L-leucyl-L-isoleucine dipeptide. After receiving these solutions, the animals were sacrificed and the GLUT-4 was analysed by western blot; additionally, glycogen, glycaemia, insulin, and free amino acids were also determined by standard methods. Of the WPH components tested, the amino acid L-isoleucine and the peptide L-leucyl-L-isoleucine showed greater efficiency in translocating GLUT-4 to the plasma membrane.
This rodent study is important because it identified L-Leu-L-Ile (not L-Ile-L-Leu) as the more active sequence isomer in the context of GLUT-4 translocation measured by western blot in skeletal muscle plasma membrane fractions. The dose used was 0.55 g/kg body mass administered by oral gavage. The study was conducted in fasted, exercise-primed animals. Limitations include the exclusively preclinical nature of the design, the small group sizes (n = 7 per group), and the fact that the mechanistic pathway was not dissected pharmacologically in this particular experiment.
The broader implication — that L-Leu-L-Ile can promote muscular glucose uptake and glycogen storage via an insulin-independent mechanism — has been replicated conceptually across multiple preclinical studies examining whey protein hydrolysates as a whole. BCAA-containing peptides in WPH, such as Ile-Val, Leu-Val, Val-Leu, Ile-Ile, Ile-Leu, Leu-Ile, and Leu-Leu, increased the rate of glucose uptake in isolated rat skeletal muscle.
Evidence level: Preclinical only (animal and patent literature); no published human clinical trials.
The glucose-uptake-promoting effects of Leu-Ile and related dipeptides have attracted interest in the context of metabolic disease. The peptide has been described in patent literature as having a preventive or therapeutic effect on diabetes mellitus or on an elevation of blood glucose level, an effect on promotion of glycogen storage, or an effect on enhancement of physical strength, enhancement of athletic ability, improvement of endurance, or relief from fatigue.
The dipeptide containing leucine and/or isoleucine is a peptide that can, upon oral administration, exhibit an action of promoting glucose uptake into cells, thereby enabling suppression of an elevation of blood glucose level. The peptide having an action of promoting glucose uptake can promote glucose uptake into cells such as muscle cells and liver cells, particularly muscle cells; in muscle cells, after insulin binds to an insulin receptor, activation of phosphoinositide 3-kinase (PI3K) downstream of an insulin receptor signal, then via several signal transductions, leads to translocation of glucose transporter-4 (GLUT-4) to the surface of a cell.
In the patent context, the active ingredient peptide was described as having a preventive or therapeutic effect on diabetes mellitus or on an elevation of blood glucose level, an effect on promotion of glycogen storage, or an effect on enhancement of physical strength, enhancement of athletic ability, improvement of endurance, or relief from fatigue.
It is essential to note that this body of evidence is drawn entirely from preclinical animal studies and patent filings; there are no published peer-reviewed randomized clinical trials in humans that have isolated Leu-Ile and tested its effects on blood glucose, insulin sensitivity, or glycogen storage in diabetic or healthy human populations.
Evidence level: Indirect (preclinical and human studies on WPH mixtures containing Leu-Ile, not isolated Leu-Ile).
Research on whey protein hydrolysate — the dietary matrix in which Leu-Ile has been identified and from which it exerts effects in preclinical models — has been extended to human clinical studies, though these studies do not test Leu-Ile in isolation.
A double-blind two-way crossover trial in ten young men (mean age 28.7 ± 3.6 years, BMI 25.2 ± 2.9 kg/m²) investigated WPH versus intact whey protein at a dose of 0.08 g/kg body weight: the aim was to determine the anabolic potency and efficacy of a novel WPH mixture on mechanistic target of rapamycin complex 1 (mTORC1) signaling and skeletal muscle protein synthesis (MPS) in healthy young subjects; ten young men were recruited into a double-blind two-way crossover trial and randomized to receive either 0.08 g/kg body weight of WPH or intact whey protein. Ingestion of WPH and whey increased mixed MPS similarly in both groups by approximately 43%. This human study does not permit attribution of observed effects to Leu-Ile specifically.
A rat study by Nakayama et al. (2019, Nutrition & Metabolism) reported that: the fractional synthetic rate (FSR) 60 minutes after ingestion of the WPH was higher than that of whey protein; moreover, at a lower dose, only the WPH ingestion caused greater MPS and phosphorylated 4E-binding protein 1 (4E-BP1) levels compared with the control group; these results indicate that ingestion of the WPH was associated with greater post-exercise MPS compared with intact whey protein, especially at lower doses.
Research groups have noted: plasma amino acid levels did not differ between the two groups, although the effects of the two diets on muscle protein synthesis varied; this result strongly suggests that not only the leucine content in dietary protein but also the molecular form of dietary protein sources may be important determinants of muscle protein synthesis; WPH contained active components that are superior to leucine itself for increasing muscle protein synthesis. This indirect evidence is consistent with a role for BCAA-containing dipeptides including Leu-Ile, but remains to be confirmed in isolation.
(Not a health-related area of use; included for completeness of scientific characterisation.)
L-Leu-L-Ile and its sequence isomers have been examined for their capacity to self-assemble into supramolecular structures. Short peptides have the ability to self-assemble to form nanostructures including hydrogels; the self-assembly of peptides composed of only hydrophobic amino acids and aliphatic protecting groups had not been investigated in detail; various aspects of nanostructures formed by N-terminal t-butyloxycarbonyl-protected aliphatic dipeptide methyl esters dissolved in various solvents were examined; depending on the sequence, position of the amino acid, and solvent of dissolution, the peptides self-assemble into superstructures such as nanotubes and needles particularly from aqueous mixtures of organic solvents. This line of research is of interest for biomaterials applications but does not bear directly on the nutritional or pharmacological properties of the compound.
L-Leu-L-Ile has been studied primarily as a component of whey protein hydrolysate preparations or as an isolated compound administered in preclinical settings. The following dosages are reported in the source literature:
No human clinical trial has established an efficacious or recommended dose for isolated L-Leu-L-Ile supplementation. Commercially available forms for research use include lyophilized powder and aqueous solutions. The dipeptide can be prepared by extraction/purification from natural products or protein hydrolysis, by chemical synthesis using solid or liquid phase peptide synthesis, or by biochemical synthesis using enzymes or microorganisms.
No formal human toxicology studies, randomized safety trials, or regulatory safety assessments specific to isolated L-Leu-L-Ile have been identified in the peer-reviewed literature or in guidance from governmental health bodies (NIH, EFSA, WHO). The following factual points are drawn from available preclinical and patent-level sources:
The table below provides an honest characterization of the evidence base for each proposed use of L-Leu-L-Ile:
Health conditions that Leucyl-L-isoleucine may help support.
Body systems that Leucyl-L-isoleucine may help support.
Go back